Literature DB >> 10943679

The effect of corticosteroid and cyclosporin A on murine corneal allograft rejection.

E P Zhang1, F Schulte, S Bulfone-Paus, F Hoffmann.   

Abstract

BACKGROUND: The immunomodulatory T-helper type 1 (Th1) cytokine interferon-gamma (IFN-gamma) was measured in serum and cornea to ascertain its general contribution to corneal graft rejection and to establish a rational basis for the decision for or against systemic therapy.
METHODS: Eight groups of differently treated BALB/c (H-2d) mice received a C3H (H-2 k) corneal graft. There was one saline-treated control group and two groups that received intramuscular cyclosporin A (CsA) for 14 or 40. Three groups received systemic or topical, systemic plus topical corticosteroid treatment, which was combined with CsA in two further groups. To measure the IFN-gamma level by enzyme-linked immunosorbent assay (ELISA), blood was taken by heart puncture and corneae were excised at the limbus.
RESULTS: Five days of systemic corticosteroid and 14 days of CsA had no significant effect on graft survival. A 40-day CsA treatment and a 40-day combined corticosteroid treatment significantly prolonged graft survival. An 80-day topical corticosteroid treatment produced additional prolongation. IFN-gamma could not be detected (limit of detection 25 pg/ml) in any of the serum samples, while significantly increased amounts of IFN-gamma were detected in the supernatants of the corneal tissue 13 or 14 days after allogeneic but not syngeneic corneal graft, corresponding to 9.5 pg, 5.1 pg and 1.8 pg per cornea.
CONCLUSION: The detection of Th1 cytokines in the cornea but not the serum of mice at the time of allograft rejection is in accordance with the finding of long-lasting dose-dependent immunosuppression of topical steroids and the inefficacy of short-term systemic CsA and corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943679     DOI: 10.1007/pl00007895

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  6 in total

Review 1.  [Immunomodulation in penetrating keratoplasty. Current status and perspectives].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

2.  [Ranking of systemic steroids after normal-risk keratoplasty. Results of a randomized prospective study].

Authors:  S Mayweg; T Reinhard; H Spelsberg; A Reis; E Godehardt; R Sundmacher
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

3.  Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival.

Authors:  Svetlana Stanojlovic; Stephan Schlickeiser; Christine Appelt; Katrin Vogt; Isabela Schmitt-Knosalla; Stefanie Haase; Thomas Ritter; Birgit Sawitzki; Uwe Pleyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-24       Impact factor: 3.117

4.  Effects of a selective glucocorticoid receptor agonist on experimental keratoplasty.

Authors:  Uwe Pleyer; Jun Yang; Sigrid Knapp; Heike Schäcke; Norbert Schmees; Natasa Orlic; Ljijana Otasevic; Maurice De Ruijter; Thomas Ritter; Sigrid Keipert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-04-09       Impact factor: 3.117

5.  3-hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival.

Authors:  Sarah S Zaher; Conrad Germain; Hongmei Fu; Daniel F P Larkin; Andrew J T George
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-22       Impact factor: 4.799

6.  Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats.

Authors:  Qing Pan; Qingguo Xu; Nicholas J Boylan; Nicholas W Lamb; David G Emmert; Jeh-Chang Yang; Li Tang; Tom Heflin; Saeed Alwadani; Charles G Eberhart; Walter J Stark; Justin Hanes
Journal:  J Control Release       Date:  2015-01-08       Impact factor: 9.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.